SLS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 10:29):

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...

Stats
Today's Volume	207 989
Average Volume	1.47M
Market Cap	83.84M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.210 ) 2024-05-09
Last Dividend	$0.420 ( 2010-12-09 )
Next Dividend	$0 ( N/A )
P/E	-1.110
ATR14	$0.0100 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Stergiou Angelos M.	Buy	159 000	Common Stock
2024-01-22	Stergiou Angelos M.	Buy	238 500	Stock Option (Right to Buy)
2024-01-22	Scheinberg David A	Buy	6 000	Common Stock
2024-01-22	Scheinberg David A	Buy	10 000	Stock Option (Right to Buy)
2024-01-22	Wood Barbara A	Buy	35 000	Common Stock

INSIDER POWER
95.64
Last 98 transactions
Buy: 3 194 450 \| Sell: 76 679

Volume Correlation

Long: -0.22 (neutral)

Short: -0.95 (very strong negative)

Signal:(42.385) Neutral

Sellas Life Sciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sellas Life Sciences Correlation - Currency/Commodity

-0.43
( neutral )

-0.50
( neutral )

0.00
( neutral )

-0.17
( neutral )

Sellas Life Sciences Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.340

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.340

FY	2022
Revenue:	$1.00M
Gross Profit:	$900 000 (90.00 %)
EPS:	$-2.10

FY	2021
Revenue:	$0.00
Gross Profit:	$-200 000 (0.00 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Sellas Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sellas Life Sciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.150	2010-09-09
Last Dividend	$0.420	2010-12-09
Next Dividend	$0	N/A
Payout Date	2010-12-20
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.570	--
Avg. Dividend % Per Year	0.00%	--
Score	1.52	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0.570	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-5.80	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-23.94	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.231	0.800	-3.85	-3.08	[1 - 3]
quickRatioTTM	0.191	0.800	-3.58	-2.86	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0473	-0.0710	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	154.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
freeCashFlowPerShareTTM	-1.242	2.00	-0.621	-1.242	[0 - 20]
debtEquityRatioTTM	-0.114	-1.500	-0.454	0.682	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-34.67	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.91

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.314	1.000	-0.234	0	[1 - 100]
returnOnEquityTTM	-23.94	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.242	2.00	-0.414	-1.242	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0384	1.500	-3.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.883

Sellas Life Sciences

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.